Cargando…

Astragaloside IV inhibits oxidized low-density lipoprotein-induced endothelial damage via upregulation of miR-140-3p

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Qian, Weibin, Qian, Qiuhai, Cai, Xinrui, Han, Ru, Yang, Wenjun, Zhang, Xinyue, Zhao, Hongmin, Zhu, Ranran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Retraction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869723/ https://www.ncbi.nlm.nih.gov/pubmed/36660951 http://dx.doi.org/10.3892/ijmm.2023.5220

Ejemplares similares

Astragaloside IV inhibits oxidized low-density lipoprotein-induced endothelial damage via upregulation of miR-140-3p
por: Qian, Weibin, et al.
Publicado: (2019)

Astragaloside IV protects endothelial progenitor cells from the damage of ox-LDL via the LOX-1/NLRP3 inflammasome pathway
por: Qian, Weibin, et al.
Publicado: (2019)

Astragaloside IV modulates TGF‐β1‐dependent epithelial‐mesenchymal transition in bleomycin‐induced pulmonary fibrosis
por: Qian, Weibin, et al.
Publicado: (2018)

Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer
por: Zhang, Wei, et al.
Publicado: (2022)

Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transition
por: Qian, Weibin, et al.
Publicado: (2020)

Astragaloside IV Protects Against Oxidized Low-Density Lipoprotein (ox-LDL)-Induced Endothelial Cell Injury by Reducing Oxidative Stress and Inflammation
por: Zhu, Zhongsheng, et al.
Publicado: (2019)

Identification and Validation of Potential Biomarkers and Pathways for Idiopathic Pulmonary Fibrosis by Comprehensive Bioinformatics Analysis
por: Qian, Weibin, et al.
Publicado: (2021)

Astragaloside IV Improves the Barrier Damage in Diabetic Glomerular Endothelial Cells Stimulated by High Glucose and High Insulin
por: Zhao, Tingting, et al.
Publicado: (2022)

[Retracted] Astragaloside IV inhibits platelet‑derived growth factor‑BB‑stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling
por: Chen, Zhuo, et al.
Publicado: (2023)

Propofol Suppresses Proliferation, Migration, Invasion and Promotes Apoptosis by Upregulating microRNA-140-5p in Gastric Cancer Cells [Retraction]
Publicado: (2021)

Metastasis‐associated protein 1 promotes epithelial‐mesenchymal transition in idiopathic pulmonary fibrosis by up‐regulating Snail expression
por: Qian, Weibin, et al.
Publicado: (2020)

Angelica Sinensis Polysaccharide Suppresses Epithelial-Mesenchymal Transition and Pulmonary Fibrosis via a DANCR/AUF-1/FOXO3 Regulatory Axis
por: Qian, Weibin, et al.
Publicado: (2020)

Correction to: Gingerol inhibits cisplatin-induced acute and delayed emesis in rats and minks by regulating the central and peripheral 5-HT, SP, and DA systems
por: Tian, Li, et al.
Publicado: (2020)

Gingerol inhibits cisplatin-induced acute and delayed emesis in rats and minks by regulating the central and peripheral 5-HT, SP, and DA systems
por: Tian, Li, et al.
Publicado: (2019)

Research progress on the mechanism of astragaloside IV in the treatment of asthma
por: Yuan, Fanyi, et al.
Publicado: (2023)

Anticancer effects and mechanisms of astragaloside-IV
por: Zhou, Liangxing, et al.
Publicado: (2022)

Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer
por: Zhang, Wei, et al.
Publicado: (2018)

Retracted: High-Density Lipoprotein Cholesterol in Young Nondiabetic Coronary Heart Disease Patients
por: Practice, Cardiology Research and
Publicado: (2023)

Effects of Astragaloside IV on heart failure in rats
por: Zhao, Zhuanyou, et al.
Publicado: (2009)

Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats
por: Liu, Wei, et al.
Publicado: (2019)

Astragaloside IV, as a potential anticancer agent
por: Xia, Dongqin, et al.
Publicado: (2023)

Pharmacological Effects of Astragaloside IV: A Review
por: Liang, Yutong, et al.
Publicado: (2023)

Molecular Mechanism of Astragaloside IV in Improving Endothelial Dysfunction of Cardiovascular Diseases Mediated by Oxidative Stress
por: Meng, Peipei, et al.
Publicado: (2021)

Accelerated Bone Regeneration by Astragaloside IV through Stimulating the Coupling of Osteogenesis and Angiogenesis
por: Wang, Feng, et al.
Publicado: (2021)

Retraction Note: Long non-coding RNA H19 deteriorates hypoxic-ischemic brain damage by interacting with microRNA-140-5p and STAT3
por: Lu, Qian, et al.
Publicado: (2023)

Retraction Notice to: MicroRNA-140 Inhibits the Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer
por: Li, Jiazhi, et al.
Publicado: (2022)

The mechanism of astragaloside IV promoting sciatic nerve regeneration
por: Zhang, Xiaohong, et al.
Publicado: (2013)

Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
por: Tan, Yu-Qing, et al.
Publicado: (2020)

Molecular mechanisms of astragaloside-IV in cancer therapy (Review)
por: Chen, Tianqi, et al.
Publicado: (2021)

Roles and Mechanisms of Astragaloside IV in Combating Neuronal Aging
por: Zaman, Qumar, et al.
Publicado: (2022)

Astragaloside IV Inhibits Bleomycin-Induced Ferroptosis in Human Umbilical Vein Endothelial Cells by Mediating LPC
por: Sheng, Shuai, et al.
Publicado: (2021)

Astragaloside IV prevents endothelial dysfunction by improving oxidative stress in streptozotocin-induced diabetic mouse aortas
por: Zhang, Yang, et al.
Publicado: (2021)

lncRNA ZEB1-AS1 promotes pulmonary fibrosis through ZEB1-mediated epithelial–mesenchymal transition by competitively binding miR-141-3p
por: Qian, Weibin, et al.
Publicado: (2019)

Comparison of Lipid Profile Parameters and Oxidized Low-Density Lipoprotein Between Normal and Preeclamptic Pregnancies in a Tertiary Care Hospital in Nepal [Retraction]
Publicado: (2020)

Astragaloside IV ameliorates renal injury in db/db mice
por: Sun, Huili, et al.
Publicado: (2016)

Astragaloside IV inhibits astrocyte senescence: implication in Parkinson’s disease
por: Xia, Mei-Ling, et al.
Publicado: (2020)

Evaluation of astragaloside IV in hepatic fibrosis: A meta-analysis
por: Han, Zhongying, et al.
Publicado: (2021)

Astragaloside IV alleviates heart failure by modulating Nrf-2
por: Feng, Wenxiao, et al.
Publicado: (2022)

Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats
por: Sun, Sen, et al.
Publicado: (2022)

Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases
por: Tan, Junlan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6cmghrbmk5brma24gr8bmqkqpe